Related Experiment Video

Updated: May 20, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer

J Mundhenk1, J Hennenlotter, L Zug

  • 1Department of Urology, Eberhard-Karls University, Tuebingen, Germany.

Oncology Letters
|August 1, 2012
PubMed

Insights

This study investigated PTEN, p-Akt, and p27(Kip1) protein expression in advanced bladder cancer (BC). PTEN intensity is a superior biomarker for Akt signaling, potentially guiding targeted therapy selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Advanced bladder cancer (BC) treatment is exploring small molecule therapies targeting EGFR and Akt signaling.
  • Understanding cellular deregulation and identifying biomarkers for therapy selection and monitoring in BC remains a challenge.
  • PTEN, p-Akt, and p27(Kip1) are potential biomarkers for Akt signaling pathway activity.

Purpose of the Study:

  • To investigate the expression of PTEN, p-Akt, and p27(Kip1) proteins in advanced bladder cancer (BC).
  • To determine the correlation between the expression of these proteins and tumor characteristics.
  • To evaluate the potential of these proteins as biomarkers for targeted therapy in BC.

Main Methods:

  • Immunohistochemical determination of PTEN, p-Akt, and p27(Kip1) expression in 86 advanced BC specimens using tissue microarrays.
  • Documentation of staining intensity, cellular frequency, and a multiplied staining score.
  • Regression analysis to correlate protein expression with tumor stage and grade.

Main Results:

  • Positive correlations were observed between PTEN and p-Akt, p-Akt and p27(Kip1), and PTEN and p27(Kip1) expression scores (p<0.02).
  • PTEN intensity showed a strong correlation with p-Akt (p=0.0003-0.0006).
  • PTEN intensity, not frequency, was a significant factor in its correlation with p27(Kip1).

Conclusions:

  • Akt activation in BC can occur independently of PTEN loss and does not necessarily decrease p27(Kip1).
  • A direct regulatory impact of PTEN on p27(Kip1) was identified.
  • PTEN intensity is a more reliable biomarker than frequency for Akt signaling in advanced BC, offering insights for targeted therapy development.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...